Celebrex®
Indications
Indicated for OA, RA, AS, AP, primary dysmenorrhea and LBP1
CELEBREX® Indications
As the cardiovascular (CV) risks of Celecoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used.
References:
- CELEBREX® HSA Approved Prescribing Information May 2021.
Mode of Action
CELEBREX® is an (NSAID) with anti-inflammatory, analgesic, and antipyretic activities1
CELEBREX® Mode of Action
CELEBREX® is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic activities1
At therapeutic concentrations, CELEBREX® does not inhibit cyclooxygenase-1 (COX-1)1
- Unlike ns-NSAIDs, CELEBREX® spares the beneficial functions of COX-1, e.g., gastric cytoprotection and platelet aggregation2,3
- Like ns-NSAIDs, CELEBREX® mediates its antipyretic, anti-inflammatory and analgesic effects by inhibiting COX-21,2
References:
- CELEBREX® HSA Approved Prescribing Information May 2021
- Warner TD, Mitchell JA. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet. 2008;371:270–273.
- Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat. 2002;68-69;165–175.
Efficacy
Chronic OA pain:
Effective relief of osteoarthritis (OA) pain within 24-48 hours1
CELEBREX®: Powerful and sustained control of pain and inflammation throughout 12 weeks2*
CELEBREX® 100 mg twice daily (BID) (n=197) demonstrated significant improvement in pain, physical function and joint stiffness, similar to naproxen 500 mg BID (n=198), as early as week 2 in patients with OA of the knee.2
*A 12-week, prospective, randomized, double-blind, parallel-group study to compare the efficacy and safety of CELEBREX® 50 mg, 100 mg, and 200 mg BID with naproxen 500 mg BID or placebo in patients with OA of the knee. Primary endpoints were patients’ global assessment of arthritic condition, patients’ assessment of pain on a VAS, and physicians’ global assessment of arthritic condition. The secondary endpoint was the WOMAC score, a multidimensional, disease-specific, self-administered health status measure assessing pain, stiffness, and physical function in patients with OA. Range of possible scores is 0-96. The range of possible scores for physical functioning is 0-68.2
BID: twice a day; NSAIDs: non-steroidal anti-inflammatory drugs; VAS: visual analog scale; WOMAC: The Western Ontario and McMaster Universities Osteoarthritis Index.
Acute pain:
CELEBREX® acted as early as 22 minutes
(median onset is about 30 minutes; range 22–33 minutes)3*
Powerful Pain Relief4
CELEBREX® 200 mg twice daily (BID) (n=147) demonstrated significant improvement in ankle pain (visual analog scale [VAS] on weight bearing)† vs placebo (n=141)‡, similar to ibuprofen 800 mg three times daily (TID) (n=155)4‡
CELEBREX® was shown to be non-inferior to ibuprofen at all time points.4§
† Patients rated their ankle pain on a 100 mm VAS from 0 (no pain) to 100 (most severe pain).
‡ p<0.05 CELEBREX® vs placebo.
§ The upper limit of the 95% confidence interval (CI) did not exceed the pre-defined limit of 20 mm.
CELEBREX® also demonstrated control of pain and inflammation in:1
• Rheumatoid arthritis
• Ankylosing spondylitis
References:
- CELEBREX® HSA Approved Prescribing Information May 2021
- Bensen WG, Fiechtner JJ, McMillen JI, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc. 1999;74:1095–1105.
- Cheung R, Krishnaswami S, Kowalski K. Analgesic efficacy of celecoxib in postoperative oral surgery pain: a single-dose, two-center, randomized, double-blind, active- and placebo-controlled study. Clin Ther. 2007;29:2498–2510.
- Ekman EF, Fiechtner JJ, Levy S, et al. Efficacy of celecoxib versus ibuprofen in the treatment of acute pain: a multicenter, double-blind, randomized controlled trial in acute ankle sprain. Am J Orthop. 2002;31(8):445–451.
Safety & Tolerability
CELEBREX® demonstrated a lower incidence of clinically significant GI AEs1,2
CELEBREX® Safety and Tolerability
Consider CELEBREX® for its superior GI tolerability profile in the elderly.3
Elderly patients experience better GI tolerability§ with CELEBREX® than naproxen, ibuprofen, or diclofenac.3
• Significantly fewer CELEBREX® patients ≥65 years (4.0%) discontinued due to any GI AEs vs ibuprofen (7.3%, p<0.05 vs CELEBREX®) or naproxen (8.1%, p<0.0001 vs CELEBREX®)3
• No statistically significant difference in discontinuation rates between CELEBREX® and diclofenac (4.2%, p=ns vs CELEBREX®)3
§ GI intolerability was defined as the combined incidence of the 5 most common GI AEs: dyspepsia, abdominal pain, diarrhea, nausea, constipation or flatulence.3
The CELEBREX® GI advantage
CELEBREX® is the only COX-2 selective NSAID that demonstrated a lower incidence of clinically significant GI AEs vs ns-NSAIDS, with or without PPI.1,2*†
Demonstrated 4X lower risk of clinically significant GI AEs vs ns-NSAIDs+PPI2†
Demonstrated ~2X lower risk of clinically significant GI AEs vs ns-NSAIDs.1*
* A double-blind, triple-dummy, parallel-group randomized trial.1
† A prospective, randomized, open-label, blinded endpoint (PROBE).2
Established with Robust Evidence
In the large PRECISION study, CELEBREX® demonstrated a similar incidence of CV events compared to naproxen or ibuprofen.4‡
Although CELEBREX® was associated with fewer APTC events, there was not a statistically significant difference between treatment arms.4
‡ PRECISION was a randomized, double-blind, parallel-group non-inferiority study evaluating the cardiovascular safety of CELEBREX® and prescription strength naproxen or ibuprofen in 24,081 osteoarthritis or rheumatoid arthritis patients with, or at high risk for cardiovascular disease, who required daily NSAID treatment to maintain their quality of life. The primary endpoint (adjudicated) was the first occurrence of an APTC endpoint, defined as a composite of cardiovascular death (including hemorrhagic death), nonfatal myocardial infarction, or nonfatal stroke. To demonstrate non-inferiority, all four of the following criteria had to be met: in the intent-to-treat analysis, (i) the point estimate of the HR had to be ≤1.12 and (ii) the upper bound of the 97.5% CI for the HR had to be ≤1.33, and in the on-treatment analysis, (iii) the point estimate of the HR had to be ≤1.12 and (iv) the upper bound of the 97.5% CI for the HR had to be ≤1.40. The protocol pre-specified a minimum follow-up time of 18 months, with censoring of data from event-free patients after 30 months in the intent-to-treat population and after 43 months in the on- treatment population.4
APTC: Antiplatelet Trialists Collaboration; BID: twice daily; CI: confidence interval; CV: cardiovascular; HR: hazard ratio; NI: non-inferiority; NSAID: non-steroidal anti-inflammatory drug; QD: once daily; TID: three times daily.
CELEBREX® is recommended by international guidelines for the management of pain in OA patients at increased GI risk, COX-2 selective NSAIDs are recommended for reduced GI toxicity.5-8
EULAR: European Alliance of Associations for Rheumatology; Osteoarthritis Research Society International, OARSI: Osteoarthritis Research Society International
References:
- Cryer B, Li C, Simon LS, et al. GI-REASONS: A novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial. Am J Gastroenterol. 2013;108(3):392–400.
- Chan FKL, Lanas A, Scheiman J, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): A randomized trial. Lancet. 2010;376(9736):173–179.
- Mallen SR, Essex MN, Zhang R. Gastrointestinal tolerability of NSAIDs in elderly patients: A pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs. Curr Med Res Opin. 2011;27(7):1359–1366.
- Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375(26):2519–2529.
- Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62:1145–1155.
- Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005;64:669–681.
- Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarth and Cart. 2008;16(2):137–162.
- Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis and cartilage. 2019;27(11):1578–1589.
Dosing & Administration
CELEBREX® capsules, at doses up to 200 mg twice per day, can be taken with or without food1.
Symptomatic Treatment of Osteoarthritis (OA):
The recommended dose of celecoxib is 200 mg administered as a single dose or as 100 mg twice per day.1
Symptomatic Relief in the Treatment of Rheumatoid Arthritis (RA):
The recommended daily dose of celecoxib is 100 mg or 200 mg twice per day.1
Ankylosing Spondylitis (AS):
The recommended dose of celecoxib is 200 mg administered as a single dose or as 100 mg twice per day.1
Management of Acute Pain in Adults:
The recommended dose of celecoxib is 400 mg, initially, followed by an additional 200 mg dose, if needed on the first day. On subsequent days, the recommended dose is 200 mg twice daily, as needed.1
Management of Chronic Low Back Pain in Adults:
The recommended dose of celecoxib is 200 or 400 mg daily, administered as a 200 mg single dose, or as 100 or 200 mg twice per day. Some patients may benefit from a total daily dose of 400 mg.1
Treatment of Primary Dysmenorrhea:
The recommended dose of celecoxib is 400 mg, initially, followed by an additional 200 mg dose, if needed on the first day. On subsequent days, the recommended dose is 200 mg twice daily, as needed.1
* As the cardiovascular (CV) risks of CELEBREX® may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used.1References:
1. CELEBREX® HSA Approved Prescribing Information May 2021.
Treatment Guidelines
CELEBREX® is recommended in International Guidelines for the management of pain 1-3
Treatment modalities for the management of OA4
- A comprehensive plan for the management of OA requires a patient-centered, multimodal and multidisciplinary approach.5
- As OA spans decades of a patient’s life, treatment is likely to consist of different pharmaceutical and nonpharmaceutical interventions, often in combination.5
- CELEBREX® is recommended in International Guidelines for the management of pain in patients with OA at an increased GI risk.1-3
References:
- Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16(2):137–162.
- Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578–1589.
- Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62(12):1145–1155.
- Gnylorybov AM, Ter-Vartanian SK, Golovach IY, et al. Expert Opinion on the Extensive Use of Prescription Crystalline Glucosamine Sulfate in the Multimodal Treatment of Osteoarthritis in Ukraine, Kazakhstan, Uzbekistan, and Armenia. Clin Med Insights Arthritis Musculoskelet Disord. 2020;13:1–9.
- Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res. 2020;72(2):149–162.
Patient Profile
Diagnosis assessments, treatment options, as well as general information about OA
A fictional OA patient case, focusing on diagnosis assessments, treatment options, as well as general information about OA1-11
References:
- Zhang W, Moskowitz RW, Nuki G et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137–62.
- Da Silva JAP and AD Woolf. Rheumatology in Practice. London: Springer, 2010.
- Graham GG et al. The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacol. 2013;21:201–232.
- Rovenský J et al. Osteoarthritis. In: Gerontorheumatology, Rovenský J, ed. Springer International Publishing Switzerland, 2017. pp.111–137.
- Calatayud S, Esplugues JV. Chemistry, pharmacodynamics, and pharmacokinetics of NSAIDs. In: NSAIDs and Aspirin, Lanas A, ed. Springer International Publishing, 2016. pp.3–16.
- Felson DT. Treatment of Osteoarthritis. In: Kelley and Firestein's Textbook of Rheumatology, Tenth Edition. Elsevier, 2017. pp.1719–1729.
- Bannuru RR et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis and Cartilage. 2019;27:1578–1589.
- Zhang W et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005;64:669–681.
- Jordan KM et al. EULAR Recommendations 2003: an evidence based approach to themanagement of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62:1145–1155.
- Scarpignato C, Blandizzi C. Adverse effects of nonsteroidal anti-inflammatory drugs on the cardiovascular system. In: NSAIDs and Aspirin, Lanas A, ed. Springer International Publishing, 2016. pp.61–89.
- Conaghan P et al. Osteoarthritis. Care and management in adults. National Institute for Health and Care Excellence. Clinical Guideline CG177. February 2014.
Patient Materials
Introduces patients to OA
Introduces patients to osteoarthritis with definitions, facts, and diagrams. It will help patients understand the condition, including its symptoms, most commonly affected joints, and treatment options. Patients are encouraged to work with their doctor to find a treatment that works well for them.1-9
Educates patients on what OA is and gives advice on how to effectively communicate with their doctor
- Details how patients can self-manage their OA with non-pharmacological options1-7
- Educates patients on what OA is and gives advice on how to effectively communicate with their doctor1-7
Overview about OA including the causes, treatments and impacts on patient quality of life1-9
- Overview about OA including the causes, treatments and impacts on patient quality of life1-9
- Based on an infographic designed by the Osteoarthritis Research Society International (OARSI)1-9
References:
- Mayo Clinic. Osteoarthritis. Accessed May 23, 2019. Available at: http://www.mayoclinic.org/diseases-conditions/osteoarthritis/home/ovc-20198248.
- World Health Organization (WHO). Chronic rheumatic conditions. May 23, 2019. Available at: http://www.who.int/chp/topics/rheumatic/en/.
- Robinson H, et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016 Oct;12(10):580-92.
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIH). Osteoarthritis. Accessed April 08, 2019. Available at: https://www.niams.nih.gov/health_info/osteoarthritis/.
- The Arthritis Society. Osteoarthritis. Accessed April 08, 2019. Available at: https://arthritis.ca/about-arthritis/arthritis-types-(a-z)/types/osteoarthritis/.
- Arthritis Foundation. Osteoarthritis Treatment. Accessed May 23, 2019. Available at: http://www.arthritis.org/about-arthritis/types/osteoarthritis/treatment.php.
- Dartmouth-Hitchcock. Osteoarthritis. Accessed April 15, 2019. Available at: https://www.dartmouth-hitchcock.org/ortho/osteoarthritis.html.
- Up to Date. Osteoarthritis Treatment (Beyond the Basics). Accessed April 08, 2019. Available at: https://www.uptodate.com/contents/osteoarthritis-treatment-beyond-the-basics?topicRef=507&source=see_link.
- Bruyère O, et al. Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritis. Drugs Aging. 2015;32(3):179-187.
References:
- US. Department of Health and Human Services. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Handout on health: osteoarthritis.2015. . Accessed June 16, 2016. http://www.niams.nih.gov/health_info/osteoarthritis/.
- Mayo Clinic. Osteoarthritis. 2016. Accessed June 16, 2016. http://www.mayoclinic.org/diseases-conditions/osteoarthritis/home/ovc-20198248.
- The Arthritis Society. Osteoarthritis, causes, symptoms and treatments. Accessed June 16, 2016. http://arthritis.ca/manage-arthritis/educational-resources-tools/printed-publications/osteoarthritis-causes-symptoms-and-treatments.
- World Health Organization (WHO). Chronic diseases and health promotion. Chronic rheumatic conditions. Accessed June 16, 2016. http://www.who.int/chp/topics/rheumatic/en/.
- United States Department of Agriculture (USDA). ChooseMyPlate.gov. Accessed June 16, 2016. http://www.choosemyplate.gov/MyPlate.
- Arthritis Foundation. Osteoarthritis treatment. Accessed June 20, 2016. http://www.arthritis.org/about-arthritis/types/osteoarthritis/treatment.php
- Arthritis Foundation. Nondrug Therapies for Knee Osteoarthritis. Accessed July 8, 2016. http://www.arthritis.org/living-with-arthritis/treatments/natural/other-therapies/nondrug-approaches-knee-oa.php
References:
- American College of Rheumatology. Osteoarthritis. Accessed April 27, 2020. Available at: https://www.rheumatology.org/I-Am-A/Patient- Caregiver/Diseases-Conditions/Osteoarthritis
- Gawker G.A. et al. Osteoarthritis is a serious disease. Clin Exp Rheumatol 2019;; 37 (Suppl. 120): S3–S6.
- Mayo Clinic. Osteoarthritis. Accessed May 23, 2019. Available at: http://www.mayoclinic.org/diseases- conditions/osteoarthritis/home/ovc-20198248.
- OARSI. White Paper – Osteoarthritis: A Serious Disease. December 1, 2016.
- Hunter DJ. et al. Osteoarthritis. Lancet 2019;;393:1745–59.
- World Health Organization (WHO). Chronic rheumatic conditions. May 23, 2019. Available at: http://www.who.int/chp/topics/rheumatic/en/.
- Veronese N. et al. Knee Osteoarthritis and Risk of Hypertension: A Longitudinal Cohort Study. Rejuvenation Res 2018;; 21(1):15–21.
- Puig-Junoy J, Zamora AR. Socio-economic costs of osteoarthritis: A systematic review of cost-of-illness studies. Semin Arthritis Rheum. 2015;;44(5):531–41.
- Arthritis Foundation. Osteoarthritis Treatment. Accessed May 23, 2019. Available at: http://www.arthritis.org/about-arthritis/
Abbreviated Prescribing Information
CELEBREX
Contents: Celecoxib Indications: Symptomatic treatment of osteoarthritis (OA) and rheumatoid arthritis (RA). Management of acute pain in adults and chronic low back pain. Primary dysmenorrhoea. Relief of signs and symptoms of ankylosing spondylitis (AS). Dosage: Adult OA 200 mg as a single dose or 100 mg twice daily. RA 100 or 200 mg twice daily. AS 200 mg as a single dose or 100 mg twice daily. Maximum (OA, RA, AS): 400 mg. Acute pain and primary dysmenorrhoea Initially 400 mg followed by 200 mg if needed on the first day. Subsequently, 200 mg twice daily as needed. Chronic low back pain 200 or 400 mg daily, administered as a 200 mg single dose or 100 or 200 mg twice daily. Total daily dose: 400 mg/day. Administration: Doses up to 200 mg twice daily can be taken with or without food. For patients with difficulty swallowing, the entire contents of the capsule can be carefully emptied onto a level teaspoon of cool/room temp applesauce/rice gruel/yogurt/mashed banana and should be ingested immediately with water. Contraindications: Hypersensitivity to celecoxib or sulfonamides. Active peptic ulceration or gastrointestinal (GI) bleeding. Patients who have experienced asthma, urticaria or allergic-type reactions after taking acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs (NSAIDs) including other cyclooxygenase-2 (COX-2) specific inhibitors. Treatment of peri-operative pain in the setting of coronary bypass graft (CABG) surgery. Congestive heart failure (CHF) (NYHA II-IV); established ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease.Special Precautions: Increased risk of serious cardiovascular (CV) thrombotic events, myocardial infarction (MI) and stroke. Monitor blood pressure during initiation and throughout the course of therapy in patients with hypertension (HTN); preexisting CHF, edema or other conditions predisposing to or worsened by fluid retention including those taking diuretics or otherwise at risk of hypovolemia. Risk of developing GI complications in patients with CV disease, concomitant use with glucocorticoids, antiplatelet drugs (such as aspirin) or other NSAIDs, alcohol; history of active GI disease eg, ulceration, GI bleeding or inflammatory conditions; concurrent therapy with anticoagulants including warfarin/coumarin-type and novel oral anticoagulants (eg, apixaban, dabigatran and rivaroxaban). Dehydration. Closely monitor patients with advanced renal disease. Severe hepatic impairment. Anaphylactoid reactions. Serious skin reactions, some of them fatal, including drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of celecoxib. Discontinue at the first appearance of skin rash, mucosal lesions or any other signs of hypersensitivity. Galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. Avoid concomitant use with non-aspirin NSAIDs. Pregnancy and lactation. Children less than 18 years. Elderly. Adverse Reactions: Bronchitis, sinusitis, upper respiratory tract infection, urinary tract infection; insomnia; dizziness; HTN (including aggravated HTN); cough; vomiting, abdominal pain, diarrhea, dyspepsia, flatulence; pruritus (including generalized pruritus), rash; peripheral oedema; ear and fungal infection, MI, angina pectoris; dyspnea, increased hepatic enzyme; muscle spasms; nephrolithiasis, vaginal haemorrhage, prostatitis, benign prostatic hyperplasia; increased blood creatinine, prostatic specific antigen and weight. Drug Interactions: Increased plasma concentration with CYP2C9 inhibitors, fluconazole and ketoconazole. Decreased plasma concentration with CYP2C9 inducers eg, rifampicin, carbamazepine and barbiturates. Increased risk of bleeding with oral anticoagulants. May diminish antihypertensive effects of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, diuretics and beta-blockers. Increased risk of nephrotoxicity with cyclosporine. Increased plasma concentration of dextromethorphan and metoprolol. Reduced natriuretic effect of furosemide and thiazides. Increased plasma levels of lithium. Presentation and Packing: Capsule 200 mg x 10's, 30's, 100's. 400 mg x 10's. Pregnancy Safety (US): C, D (in third trimester or near delivery)
API-CEL-SIN-0321/0
References:
- CELEBREX® HSA Approved Prescribing Information May 2021.
Featured Content
Efficacy
Control of pain and inflammation across many indications1
Safety & Tolerability
CELEBREX® demonstrated a lower incidence of clinically significant GI AEs1,2
Mode of Action
Celebrex® is an (NSAID) with anti-inflammatory, analgesic, and antipyretic activities1